-
FDA Approves mFLUSIVA (influenza vaccine, mRNA) for the Prevention of Seasonal Influenza
NASDAQ: $MRNA CAMBRIDGE, MA / ACCESS Newswire / August 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults… Source: Read More
-
IDEAYA | Announces Agenda for Investor R&D Day Webcast on December 4, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company dedicated to the discovery and development of targeted therapeutics, is pleased to announce the agenda topics for its upcoming Investor R&D Day. This highly anticipated webcast event, hosted by IDEAYA, will take place on Monday, December 4, 2023, from 8:00 am to 9:30 am…